CSTL

SEC source: 0001447362-22-000129 · wf-form4_165956079250648.xml · nonDerivative · entry 7

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold

Disclosed balance after: 30,181

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022.

F2 · price: This transaction was executed in multiple trades at prices ranging from $27.055 to $27.950, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F9 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.

SEC source: 0001447362-22-000129 · wf-form4_165956079250648.xml · nonDerivative · entry 6

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold

Disclosed balance after: 30,181

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022.

F2 · price: This transaction was executed in multiple trades at prices ranging from $27.055 to $27.950, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F8 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.

SEC source: 0001447362-22-000129 · wf-form4_165956079250648.xml · nonDerivative · entry 5

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold

Disclosed balance after: 30,181

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022.

F2 · price: This transaction was executed in multiple trades at prices ranging from $27.055 to $27.950, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F7 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.

SEC source: 0001447362-22-000129 · wf-form4_165956079250648.xml · nonDerivative · entry 4

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk

Disclosed balance after: 30,181

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022.

F2 · price: This transaction was executed in multiple trades at prices ranging from $27.055 to $27.950, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F6 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary.

SEC source: 0001447362-22-000129 · wf-form4_165956079250648.xml · nonDerivative · entry 3

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust

Disclosed balance after: 136,266

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022.

F2 · price: This transaction was executed in multiple trades at prices ranging from $27.055 to $27.950, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries.

SEC source: 0001447362-22-000129 · wf-form4_165956079250648.xml · nonDerivative · entry 2

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By The Maetzold Descendants 2020 Trust

Disclosed balance after: 148,746

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022.

F2 · price: This transaction was executed in multiple trades at prices ranging from $27.055 to $27.950, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries.

SEC source: 0001447362-22-000129 · wf-form4_165956079250648.xml · nonDerivative · entry 1

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 328,814

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022.

F2 · price: This transaction was executed in multiple trades at prices ranging from $27.055 to $27.950, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · balance_after: On May 26, 2022, the Reporting Person transferred 55,603 shares of Castle Biosciences, Inc. common stock from DJM Grantor Retained Annuity Trust No. 2 and 75,000 shares from DJM Grantor Retained Annuity Trust No. 3 to his direct holdings.

SEC source: 0001447362-22-000127 · wf-form4_165956018379867.xml · nonDerivative · entry 1

BRADBURY DANIEL · CIK 0001236397 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By LLC

Disclosed balance after: 238,059

F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC on June 8, 2022.

F2 · price: This transaction was executed in multiple trades at prices ranging from $27.09 to $27.97, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · ownership.nature: Held by BioBrit, LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares.

SEC source: 0001447362-22-000125 · wf-form4_165819097317061.xml · derivative · entry 2

Goldberg Ellen · CIK 0001867100 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 880

Underlying: Common Stock · 440 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: On July 14, 2021, the Reporting Person was granted 1,320 RSUs which vest in three equal annual installments beginning on July 14, 2022.

F2 · derivative.expiration_date: On July 14, 2021, the Reporting Person was granted 1,320 RSUs which vest in three equal annual installments beginning on July 14, 2022.

SEC source: 0001447362-22-000125 · wf-form4_165819097317061.xml · nonDerivative · entry 1

Goldberg Ellen · CIK 0001867100 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 440

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

SEC source: 0001447362-22-000124 · wf-form4_165819092714417.xml · derivative · entry 2

Caple Kim · CIK 0001867184 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 880

Underlying: Common Stock · 440 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: On July 14, 2021, the Reporting Person was granted 1,320 RSUs which vest in three equal annual installments beginning on July 14, 2022

F2 · derivative.expiration_date: On July 14, 2021, the Reporting Person was granted 1,320 RSUs which vest in three equal annual installments beginning on July 14, 2022

SEC source: 0001447362-22-000124 · wf-form4_165819092714417.xml · nonDerivative · entry 1

Caple Kim · CIK 0001867184 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 440

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

SEC source: 0001447362-22-000119 · wf-form4_165516163823641.xml · derivative · entry 2

Harrison Miles · CIK 0001808228 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 830 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: The RSUs vested in full on the one-year anniversary of the date of grant on June 10, 2022.

F2 · derivative.expiration_date: The RSUs vested in full on the one-year anniversary of the date of grant on June 10, 2022.

SEC source: 0001447362-22-000119 · wf-form4_165516163823641.xml · nonDerivative · entry 1

Harrison Miles · CIK 0001808228 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 830

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001447362-22-000115 · wf-form4_165516141244033.xml · derivative · entry 5

BRADBURY DANIEL · CIK 0001236397 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 830 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: The RSUs vested in full on the one-year anniversary of the date of grant on June 10, 2022.

F5 · derivative.expiration_date: The RSUs vested in full on the one-year anniversary of the date of grant on June 10, 2022.

SEC source: 0001447362-22-000115 · wf-form4_165516141244033.xml · nonDerivative · entry 1

BRADBURY DANIEL · CIK 0001236397 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 830

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001447362-22-000117 · wf-form4_165516151693035.xml · derivative · entry 2

Cole G Bradley · CIK 0001337798 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 830 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: The RSUs vested in full on the one-year anniversary of the date of grant on June 10, 2022.

F2 · derivative.expiration_date: The RSUs vested in full on the one-year anniversary of the date of grant on June 10, 2022.

SEC source: 0001447362-22-000117 · wf-form4_165516151693035.xml · nonDerivative · entry 1

Cole G Bradley · CIK 0001337798 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 830

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001447362-22-000113 · wf-form4_165516131716488.xml · derivative · entry 2

Aspinall Mara G. · CIK 0001623049 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 830 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: The RSUs vested in full on the one-year anniversary of the date of grant on June 10, 2022.

F2 · derivative.expiration_date: The RSUs vested in full on the one-year anniversary of the date of grant on June 10, 2022.

SEC source: 0001447362-22-000113 · wf-form4_165516131716488.xml · nonDerivative · entry 1

Aspinall Mara G. · CIK 0001623049 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,678

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001447362-22-000104 · wf-form4_165455749120636.xml · derivative · entry 2

Harrison Miles · CIK 0001808228 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,825

Underlying: Common Stock · 3,825 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: The RSUs vest in full on the one-year anniversary of the date of grant on June 2, 2023.

F2 · derivative.expiration_date: The RSUs vest in full on the one-year anniversary of the date of grant on June 2, 2023.

SEC source: 0001447362-22-000104 · wf-form4_165455749120636.xml · derivative · entry 1

Harrison Miles · CIK 0001808228 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,647

Underlying: Common Stock · 7,647 shares

Expires 2032-06-01

SEC source: 0001447362-22-000106 · wf-form4_165455767863784.xml · derivative · entry 2

Olson Tiffany · CIK 0001442172 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,825

Underlying: Common Stock · 3,825 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: The RSUs vest in full on the one-year anniversary of the date of grant on June 2, 2023.

F2 · derivative.expiration_date: The RSUs vest in full on the one-year anniversary of the date of grant on June 2, 2023.

SEC source: 0001447362-22-000106 · wf-form4_165455767863784.xml · derivative · entry 1

Olson Tiffany · CIK 0001442172 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,647

Underlying: Common Stock · 7,647 shares

Expires 2032-06-01

SEC source: 0001447362-22-000102 · wf-form4_165455736738177.xml · derivative · entry 2

Goldberg Ellen · CIK 0001867100 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,825

Underlying: Common Stock · 3,825 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: The RSUs vest in full on the one-year anniversary of the date of grant on June 2, 2023.

F2 · derivative.expiration_date: The RSUs vest in full on the one-year anniversary of the date of grant on June 2, 2023.

SEC source: 0001447362-22-000102 · wf-form4_165455736738177.xml · derivative · entry 1

Goldberg Ellen · CIK 0001867100 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,647

Underlying: Common Stock · 7,647 shares

Expires 2032-06-01

SEC source: 0001447362-22-000100 · wf-form4_165455722481109.xml · derivative · entry 2

Cole G Bradley · CIK 0001337798 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,825

Underlying: Common Stock · 3,825 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: The RSUs vest in full on the one-year anniversary of the date of grant on June 2, 2023.

F2 · derivative.expiration_date: The RSUs vest in full on the one-year anniversary of the date of grant on June 2, 2023.

SEC source: 0001447362-22-000100 · wf-form4_165455722481109.xml · derivative · entry 1

Cole G Bradley · CIK 0001337798 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,647

Underlying: Common Stock · 7,647 shares

Expires 2032-06-01

SEC source: 0001447362-22-000094 · wf-form4_165455679589646.xml · derivative · entry 2

Aspinall Mara G. · CIK 0001623049 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,825

Underlying: Common Stock · 3,825 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: The RSUs vest in full on the one-year anniversary of the date of grant on June 2, 2023.

F2 · derivative.expiration_date: The RSUs vest in full on the one-year anniversary of the date of grant on June 2, 2023.

SEC source: 0001447362-22-000094 · wf-form4_165455679589646.xml · derivative · entry 1

Aspinall Mara G. · CIK 0001623049 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,647

Underlying: Common Stock · 7,647 shares

Expires 2032-06-01

SEC source: 0001447362-22-000096 · wf-form4_165455692068765.xml · derivative · entry 2

BRADBURY DANIEL · CIK 0001236397 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,825

Underlying: Common Stock · 3,825 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: The RSUs vest in full on the one-year anniversary of the date of grant on June 2, 2023.

F2 · derivative.expiration_date: The RSUs vest in full on the one-year anniversary of the date of grant on June 2, 2023.

SEC source: 0001447362-22-000096 · wf-form4_165455692068765.xml · derivative · entry 1

BRADBURY DANIEL · CIK 0001236397 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,647

Underlying: Common Stock · 7,647 shares

Expires 2032-06-01

SEC source: 0001447362-22-000098 · wf-form4_165455706326198.xml · derivative · entry 2

Caple Kim · CIK 0001867184 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,825

Underlying: Common Stock · 3,825 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: The RSUs vest in full on the one-year anniversary of the date of grant on June 2, 2023.

F2 · derivative.expiration_date: The RSUs vest in full on the one-year anniversary of the date of grant on June 2, 2023.

SEC source: 0001447362-22-000098 · wf-form4_165455706326198.xml · derivative · entry 1

Caple Kim · CIK 0001867184 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,647

Underlying: Common Stock · 7,647 shares

Expires 2032-06-01

SEC source: 0001447362-22-000089 · wf-form4_165273230340927.xml · derivative · entry 2

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,712

Underlying: Common Stock · 4,000 shares

Expires 2029-03-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 25% of the 28,712 shares originally subject to the option vested on March 13, 2020, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001447362-22-000089 · wf-form4_165273230340927.xml · nonDerivative · entry 1

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,775

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001447362-22-000121 · wf-form4_165723586747906.xml · nonDerivative · entry 2

Olson Tiffany · CIK 0001442172 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,806

SEC source: 0001447362-22-000121 · wf-form4_165723586747906.xml · nonDerivative · entry 1

Olson Tiffany · CIK 0001442172 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,586

SEC source: 0001447362-22-000087 · wf-form4_165238710755304.xml · derivative · entry 2

Olson Tiffany · CIK 0001442172 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 974

Underlying: Common Stock · 486 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: On May 10, 2021, the Reporting Person was granted 1,460 RSUs, which vest in three equal annual installments beginning on May 10, 2022.

F2 · derivative.expiration_date: On May 10, 2021, the Reporting Person was granted 1,460 RSUs, which vest in three equal annual installments beginning on May 10, 2022.

SEC source: 0001447362-22-000087 · wf-form4_165238710755304.xml · nonDerivative · entry 1

Olson Tiffany · CIK 0001442172 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 486

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

SEC source: 0001447362-22-000068 · wf-form4_165118849087804.xml · nonDerivative · entry 1

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 201,934

F1 · shares: The reporting person acquired 22,311 shares of common stock on April 26, 2022, as consideration for the Reporting Person's equity securities of AltheaDx, Inc. ("AltheaDx"), which Castle Biosciences, Inc. ("Castle Biosciences") acquired by merger on April 26, 2022 (the "Merger") pursuant to an Agreement and Plan of Merger agreement dated April 4, 2022 (the "Merger Agreement"). Of the 22,311 shares issued to the Reporting Person in the Merger, 1,895 shares are currently being held in escrow and are subject to forfeiture for a specified period following the Merger to satisfy indemnification claims arising of Castle Biosciences, if any.

F2 · shares: The Merger Agreement provides that the former securityholders of AltheaDx may receive additional consideration, payable 50% in cash and 50% in shares of common stock of Castle Biosciences, based on the achievement of certain commercial milestones with related dates or performance periods through December 31, 2024 (the "Milestone Payments"). The portion of the Milestone Payments payable in shares of common stock will be valued at the volume-weighted average price for the 20 trading days ending as of the applicable determination date. The number of shares issuable is subject to certain limitations set forth in the Merger Agreement. The Reporting Person's right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on April 26, 2022, the effective date of the merger.

F3 · price: The number of shares issuable was determined pursuant to a formula set forth in the Merger Agreement, which provided that, for the purpose of determining the number of shares issuable, the shares of Castle Biosciences common stock would be valued at $42.54, which represents the volume weighted average share price of the stock for the 20 trading days immediately preceding the date of the Merger Agreement.

F4 · balance_after: On March 2, 2022, and March 3, 2022, the DJM Grantor Retained Annuity Trust No. 2 made annuity payments to the Reporting Person by transferring a total of 44,397 shares of Castle Biosciences, Inc. common stock to his direct holdings.

SEC source: 0001447362-22-000072 · wf-form4_165118923180398.xml · nonDerivative · entry 1

Stokes Frank · CIK 0001782815 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,775

F1 · shares: The reporting person acquired 1,114 shares of common stock on April 26, 2022, as consideration for the Reporting Person's equity securities of AltheaDx, Inc. ("AltheaDx"), which Castle Biosciences, Inc. ("Castle Biosciences") acquired by merger on April 26, 2022 (the "Merger") pursuant to an Agreement and Plan of Merger agreement dated April 4, 2022 (the "Merger Agreement"). Of the 1,114 shares issued to the Reporting Person in the Merger, 94 shares are currently being held in escrow and are subject to forfeiture for a specified period following the Merger to satisfy indemnification claims arising of Castle Biosciences, if any.

F2 · shares: The Merger Agreement provides that the former securityholders of AltheaDx may receive additional consideration, payable 50% in cash and 50% in shares of common stock of Castle Biosciences, based on the achievement of certain commercial milestones with related dates or performance periods through December 31, 2024 (the "Milestone Payments"). The portion of the Milestone Payments payable in shares of common stock will be valued at the volume-weighted average price for the 20 trading days ending as of the applicable determination date. The number of shares issuable is subject to certain limitations set forth in the Merger Agreement. The Reporting Person's right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on April 26, 2022, the effective date of the merger.

F3 · price: The number of shares issuable was determined pursuant to a formula set forth in the Merger Agreement, which provided that, for the purpose of determining the number of shares issuable, the shares of Castle Biosciences common stock would be valued at $42.54, which represents the volume weighted average share price of the stock for the 20 trading days immediately preceding the date of the Merger Agreement.

F4 · balance_after: Includes 331 shares acquired on February 28, 2022, under the Issuer's employee stock purchase plan.

SEC source: 0001447362-22-000070 · wf-form4_165118889230689.xml · nonDerivative · entry 1

Oelschlager Kristen M · CIK 0001856565 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,873

F1 · shares: The reporting person acquired 6,692 shares of common stock on April 26, 2022, as consideration for the Reporting Person's equity securities of AltheaDx, Inc. ("AltheaDx"), which Castle Biosciences, Inc. ("Castle Biosciences") acquired by merger on April 26, 2022 (the "Merger") pursuant to an Agreement and Plan of Merger agreement dated April 4, 2022 (the "Merger Agreement"). Of the 6,692 shares issued to the Reporting Person in the Merger, 568 shares are currently being held in escrow and are subject to forfeiture for a specified period following the Merger to satisfy indemnification claims arising of Castle Biosciences, if any.

F2 · shares: The Merger Agreement provides that the former securityholders of AltheaDx may receive additional consideration, payable 50% in cash and 50% in shares of common stock of Castle Biosciences, based on the achievement of certain commercial milestones with related dates or performance periods through December 31, 2024 (the "Milestone Payments"). The portion of the Milestone Payments payable in shares of common stock will be valued at the volume-weighted average price for the 20 trading days ending as of the applicable determination date. The number of shares issuable is subject to certain limitations set forth in the Merger Agreement. The Reporting Person's right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on April 26, 2022, the effective date of the merger.

F3 · price: The number of shares issuable was determined pursuant to a formula set forth in the Merger Agreement, which provided that, for the purpose of determining the number of shares issuable, the shares of Castle Biosciences common stock would be valued at $42.54, which represents the volume weighted average share price of the stock for the 20 trading days immediately preceding the date of the Merger Agreement.

F4 · balance_after: Includes 407 shares acquired on February 28, 2022, under Castle Biosciences' employee stock purchase plan.

SEC source: 0001447362-22-000066 · wf-form4_165118794332101.xml · nonDerivative · entry 1

Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Tobin W and Susan M Juvenal Family Revocable Trust

Disclosed balance after: 2,230

F1 · shares: The reporting person acquired 2,230 shares of common stock on April 26, 2022, as consideration for the Reporting Person's equity securities of AltheaDx, Inc. ("AltheaDx"), which Castle Biosciences, Inc. ("Castle Biosciences") acquired by merger on April 26, 2022 (the "Merger") pursuant to an Agreement and Plan of Merger agreement dated April 4, 2022 (the "Merger Agreement"). Of the 2,230 shares issued to the Reporting Person in the Merger, 189 shares are currently being held in escrow and are subject to forfeiture for a specified period following the Merger to satisfy indemnification claims arising of Castle Biosciences, if any.

F2 · shares: The Merger Agreement provides that the former securityholders of AltheaDx may receive additional consideration, payable 50% in cash and 50% in shares of common stock of Castle Biosciences, based on the achievement of certain commercial milestones with related dates or performance periods through December 31, 2024 (the "Milestone Payments"). The portion of the Milestone Payments payable in shares of common stock will be valued at the volume-weighted average price for the 20 trading days ending as of the applicable determination date. The number of shares issuable is subject to certain limitations set forth in the Merger Agreement. The Reporting Person's right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on April 26, 2022, the effective date of the merger.

F3 · price: The number of shares issuable was determined pursuant to a formula set forth in the Merger Agreement, which provided that, for the purpose of determining the number of shares issuable, the shares of Castle Biosciences common stock would be valued at $42.54, which represents the volume weighted average share price of the stock for the 20 trading days immediately preceding the date of the Merger Agreement.

F4 · ownership.nature: Held by Tobin W and Susan M Juvenal Family Revocable Trust of which the Reporting Person and his spouse are the trustees and the Reporting Person, his spouse and their children are the beneficiaries.

SEC source: 0001447362-22-000064 · wf-form4_165118746292566.xml · nonDerivative · entry 1

BRADBURY DANIEL · CIK 0001236397 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By LLC

Disclosed balance after: 246,249

F1 · shares: The reporting person acquired 60,997 shares of common stock on April 26, 2022, as consideration for the Reporting Person's equity securities of AltheaDx, Inc. ("AltheaDx"), which Castle Biosciences, Inc. ("Castle Biosciences") acquired by merger on April 26, 2022 (the "Merger") pursuant to an Agreement and Plan of Merger agreement dated April 4, 2022 (the "Merger Agreement"). Of the 60,997 shares issued to the Reporting Person in the Merger, 5,181 shares are currently being held in escrow and are subject to forfeiture for a specified period following the Merger to satisfy indemnification claims arising of Castle Biosciences, if any.

F2 · shares: The Merger Agreement provides that the former securityholders of AltheaDx may receive additional consideration, payable 50% in cash and 50% in shares of common stock of Castle Biosciences, based on the achievement of certain commercial milestones with related dates or performance periods through December 31, 2024 (the "Milestone Payments"). The portion of the Milestone Payments payable in shares of common stock will be valued at the volume-weighted average price for the 20 trading days ending as of the applicable determination date. The number of shares issuable is subject to certain limitations set forth in the Merger Agreement. The Reporting Person's right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on April 26, 2022, the effective date of the merger.

F3 · price: The number of shares issuable was determined pursuant to a formula set forth in the Merger Agreement, which provided that, for the purpose of determining the number of shares issuable, the shares of Castle Biosciences common stock would be valued at $42.54, which represents the volume weighted average share price of the stock for the 20 trading days immediately preceding the date of the Merger Agreement.

F4 · ownership.nature: Held by BioBrit, LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares.

SEC source: 0001447362-22-000052 · wf-form4_164876446391978.xml · nonDerivative · entry 7

BRADBURY DANIEL · CIK 0001236397 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Annette Bradbury Irrecovable Descendant's Trust

Disclosed balance after: 97,562

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021.

F11 · price: This transaction was executed in multiple trades at prices ranging from $45.690 to $46.415, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F7 · ownership.nature: Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries.

SEC source: 0001447362-22-000052 · wf-form4_164876446391978.xml · nonDerivative · entry 6

BRADBURY DANIEL · CIK 0001236397 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Daniel Bradbury Irrecovable Descendant's Trust

Disclosed balance after: 97,537

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021.

F10 · price: This transaction was executed in multiple trades at prices ranging from $45.520 to $45.690, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5 · ownership.nature: Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries.

SEC source: 0001447362-22-000052 · wf-form4_164876446391978.xml · nonDerivative · entry 5

BRADBURY DANIEL · CIK 0001236397 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Daniel Bradbury Irrecovable Descendant's Trust

Disclosed balance after: 98,049

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021.

F9 · price: This transaction was executed in multiple trades at prices ranging from $44.520 to $45.510, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5 · ownership.nature: Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries.

SEC source: 0001447362-22-000052 · wf-form4_164876446391978.xml · nonDerivative · entry 4

BRADBURY DANIEL · CIK 0001236397 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By LLC

Disclosed balance after: 185,252

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021.

F8 · price: This transaction was executed in multiple trades at prices ranging from $43.630 to $44.520, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares.

SEC source: 0001447362-22-000052 · wf-form4_164876446391978.xml · nonDerivative · entry 3

BRADBURY DANIEL · CIK 0001236397 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Annette Bradbury Irrecovable Descendant's Trust

Disclosed balance after: 100,062

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021.

F6 · price: This transaction was executed in multiple trades at prices ranging from $45.880 to $46.140, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F7 · ownership.nature: Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries.